Reshma L. Mahtani DO
Chief of Breast Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FloridaDr. Reshma L. Mahtani is a medical oncologist practicing in South Florida. She serves as Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida (a Memorial Sloane Kettering affiliate). She specializes in the treatment of breast cancer.
Prior to assuming her role at the Miami Cancer Institute, Dr. Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She is an active clinical researcher, and her research focuses on novel therapies for the treatment of breast cancer. She has made significant scientific and clinical practice contributions with numerous first-author publications in peer-reviewed journals.
She has served on the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee and as a member of the editorial board of The Breast Journal. She has been Program Director for several officially licensed Best of ASCO programs and is the Director of the ASCO Highlights series.
After completing her Master of Science degree in neuroscience at the University of Connecticut, Dr. Mahtani went on to the University of New England College of Osteopathic Medicine, where she received her medical degree. She completed internship at Greenwich Hospital, a Yale-affiliate, in Greenwich, Connecticut, and undertook residency training at St. Vincent’s Catholic Medical Center in New York, where she also completed her fellowship.
Disclosures
- Consultant/advisory role: Agendia; Amgen; AstraZeneca; Daiichi; Eisai; Gilead; Hologic; Lilly; Merck; Novartis; Pfizer; Puma; Sanofi; Sermonix; Stemline; Seagen
- Contracted research: Gilead
Recent Contributions to PracticeUpdate:
- Enzalutamide Is Clinically Active and Tolerable in AR-Expressing TNBC
- Current Concepts in Genomic Profiling for Breast Cancer
- The Role of Palbociclib in Advanced Breast Cancer With and Without Visceral Metastases
- Role of Bone-Modifying Agents in Metastatic Breast Cancer
- HER2 Blockade With Lapatinib, Trastuzumab, and an Aromatase Inhibitor Improves PFS in Postmenopausal Women With HER2-Positive, HR-Positive Metastatic Breast Cancer
- Preservation of Function in Breast Cancer Patients: New Insights From SABCS 2017
- Key Trials in Metastatic Breast Cancer From SABCS 2017
- 2017 Top Stories in Metastatic Breast Cancer: The Potential for Immunotherapy in Breast Cancer
- SABCS 2017: Recommendations From Dr. Reshma Mahtani
- SABCS 2017: Recommendations From Dr. Reshma Mahtani: Treatment